US 11,865,123 B2
Methods of inhibiting pathological angiogenesis
Pam Tsuruda, South San Francisco, CA (US); Jill Hopkins, South San Francisco, CA (US); Harry Sweigard, South San Francisco, CA (US); Yan Poon, South San Francisco, CA (US); Jamie Dananberg, South San Francisco, CA (US); Daniel Marquess, South San Francisco, CA (US); and Nathaniel David, South San Francisco, CA (US)
Assigned to Unity Biotechnology, Inc., South San Francisco, CA (US)
Filed by Unity Biotechnology, Inc., South San Francisco, CA (US)
Filed on Aug. 25, 2021, as Appl. No. 17/412,003.
Application 17/412,003 is a division of application No. 16/791,960, filed on Feb. 14, 2020, granted, now 11,129,838.
Application 16/791,960 is a division of application No. 16/160,840, filed on Oct. 15, 2018, granted, now 10,588,916, issued on Mar. 17, 2020.
Application 16/160,840 is a continuation of application No. PCT/US2018/046553, filed on Aug. 13, 2018.
Claims priority of provisional application 62/579,793, filed on Oct. 31, 2017.
Prior Publication US 2022/0072015 A1, Mar. 10, 2022
Int. Cl. A61K 31/635 (2006.01); A61P 27/02 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 47/20 (2006.01); A61K 47/10 (2017.01)
CPC A61K 31/635 (2013.01) [A61P 27/02 (2018.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 47/10 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01)] 6 Claims
 
1. A method of promoting vascular repair in an eye of a subject in need thereof, comprising administering a therapeutically effective dose of a pharmaceutical composition comprising a compound selected from:

OG Complex Work Unit Chemistry
and phosphorylated forms and pharmaceutically acceptable salts thereof; and

OG Complex Work Unit Chemistry
and pharmaceutically acceptable salts thereof.